According to a report by Grand
View Research, Inc., the global circulating
tumor cells (CTC) market is estimated to reach a valuation of
USD 11.55 billion by 2022. Growing requirement for advanced diagnostic
techniques to timely detect and monitor chronic diseases such as cancer is
anticipated to propel the market during the forecast period (2017 to 2022).
Circulating tumor cells can be used to determine progression rate of disease
and therapy required to eradicate tumor. CTC tests possess the ability to
quantify, detect, and analyze tumor cells inside patient’s blood.
Rising cases of chronic
oncology dependent on detection and analysis of CTCs can foster the growth of
the market in the coming years. Growing development in the field of biomedical
imaging and biomedical engineering can influence the growth of the market
positively. High demand for preventive medicines through timely and accurate
diagnosis of tumor can augment the market. Development of tumor markers that
can be used with companion diagnostics to monitor and diagnose different forms
of tumor can stimulate market growth.
Growing number of patented
research institutes is projected to drive the market. Rising preference for CTC
tests for real-time monitoring of cancer therapy to conventional methods such
as tumor tissue biopsy and imaging technologies is poised to help the market
gain tremendous traction over the coming years. Introduction of novel
biotechnological methods, which can enable quantitation and isolation of
circulating tumor cells, can escalate the growth of the market.
Access Research Report of Circulating Tumor Cells Market @: www.grandviewresearch.com/industry-analysis/circulating-tumor-cells-market
The global circulating tumor
cells (CTCs) market can be segmented on the basis of technology, application,
and region. Based on technology, the market can be divided into CTC detection,
CTC enrichment, and CTC analysis. In 2016, CTC enrichment methods commanded
45.0% of the market share in terms of revenue. It is expected to witness
significant growth during the forecast period. Development of enriched CTCs can
enable its functional characterization to support disease interrogation and
target therapy. It can be further classified into negative depletion, positive
depletion, and a combination of both techniques. Growing use of enrichment
approaches for CTC detection in biotechnology research establishments owing to
high accuracy can support the growth of the overall market during the forecast
period.
Based on application, the
market can be segmented into EMT biomarkers development, tumorigenesis
research, cancer stem cell research, and others. Introduction of new
technologies such as capturing CTC clusters from unprocessed blood using
molecular biology technique is likely to facilitate robust detection of CTCs.
Growing standard of methodology to expedite multicenter trials is estimated to
promote clinical utility of CTC.
Browse more reports of this category by
Grand View Research at: www.grandviewresearch.com/industry/biotechnology
Increasing number of R&D
activities to develop high-end collection techniques can work in favor of the
market. Moreover, use of screen cell technology, biomarker development, and
tumorigenesis research are anticipated to trigger the growth of the market
during the forecast period.
From a geographical viewpoint,
the market can be categorized into North America, Asia Pacific, Europe, Latin America,
and Middle East & Africa (MEA). In 2016, North America dominated the market
and accounted for 48.0% of the market. High-end healthcare infrastructure
coupled with domicile of a large number of key players is contributing to the
growth of the regional market. In addition, growing awareness among patients
and increasing R&D investments to discover new drugs can escalate market
growth in the region during the forecast period. Moreover, supportive
initiatives from local government in terms of R&D funding for clinical
diagnostic products are projected to provide an upthrust to the market in North
America.
In Asia Pacific, the market is
poised to register a phenomenal CAGR of 13.4% in the coming years owing to
mounting cases of cancer in developing countries of this region. Factors such
as expanding base of geriatric population and changing lifestyles can be
attributed for rise in the number of cancer patients. Besides this,
infrastructure development in care centers and growing adoption of CTC
diagnostic tests can supplement the growth of the market. Moreover, continuous
efforts from countries such as Japan and China to develop advanced techniques
to detect and monitor cancer is expected to spur the growth of the market in
this region.
Some of the leading companies
in the market are Advanced Cell Diagnostics, Aviva Biosciences, Silicon
Biosystems, Janssen Diagnostics, and Sysmex Corporation. Most companies are
likely to collaborate with university-based research institutes and hospitals
to develop novel technologies for CTC enrichment and detection.
Access
Press Release of Circulating Tumor Cells Market @: www.grandviewresearch.com/press-release/global-circulating-tumor-cells-market
About Grand View Research
Grand View Research, Inc. is a
U.S. based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides
syndicated research reports, customized research reports, and consulting
services. To help clients make informed business decisions, we offer market
intelligence studies ensuring relevant and fact-based research across a range
of industries, from technology to chemicals, materials and healthcare.
For More Information: www.grandviewresearch.com
No comments:
Post a Comment